Sequential administration of temozolomide and fotemustine: Depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours

Annals of Oncology

Volumn 10, Issue 7, 1999, Pages 831-838

  Gander, M ^a   Leyvraz, S ^a   Decosterd, L ^a   Bonfanti, M ^b   Marzolini, C ^a   Shen, F ^a   Lienard D ^a   Perey, L ^a   Colella, G ^b   Biollaz, J ^a   Lejeune, F ^a   Yarosh, D ^c   Belanich, M ^c   D'Incalci, M ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c AGI Dermatics   (United States)

Author keywords

Melanoma; Pharmacodynamics; Pharmacokinetics; Temozolomide

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; DACARBAZINE; FOTEMUSTINE; ONDANSETRON; TEMOZOLOMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME BLOOD LEVEL; FEMALE; GLIOMA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MELANOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0032793312     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008304032421     Document Type: Article

References (40)

1. Berger NA. Alkylating agents. In De Vita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology. Philadelphia: JB Lippincott 1993; 400-9.
2. Kohn KW. Interstrand cross-linking of DNA by 1,3-bis (2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res 1977; 37: 1450-4.
3. 1-deoxyguanosinyl)ethane in DNA treated with N,N′-bis (2-chloroethyl)-N-nitrosourea. Cancer Res 1982; 42: 3102-5.
4. Erickson LC, Laurent G, Sharkey NA, Kohn KW. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature 1980; 288: 727-9.
5. 6-alkyl guanine alkyltransferase (AT) in cancer chemotherapy. Cancer Treat Rev 1988; 15: 279-92.
6. 6-methylguanine to a protein cysteine residue. J Biol Chem 1980; 255: 10569-71.
7. 6-methylguanine-DNA methyltransferase in human cells. Mutat Res 1984; 131: 27-36.
8. 6-methylguanine-DNA-methyltransferase activity and resistance of human cells to the cytotoxic and mutagenic effect of N-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis 1984; 5: 1641-7.
9. 6-alkylguanine-DNA alkyl transferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Proc Natl Acad Sci USA 1985; 82: 2985-9.
10. 6-alkylguanine-DNA alkyltransferase in a cell line sensitive to alkylating agents. Carcinogenesis 1989; 10: 1613-9.
11. 6-Alkylguanine-DNA alkyl transferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg 1989; 70: 573-7.
12. Zlotogorski C, Erickson LC. Pretreatment of human colon tumor cells with DNA methylating agents inhibits their ability to repair chloroethyl monoadducts. Carcinogenesis (London) 1984; 5: 83-7.
13. 6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 1990; 87: 5368-72.
14. 6-alkylguanine-DNA alkyltransferase in vivo by pretreatment with antineoplastic agents. Biochem Pharmacol 1989; 38: 929-34.
15. Gerard B, Aamdal S, Lee SM et al. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - dacarbazine and fotemustine - in patients with melanoma. Eur J Cancer 1993; 29A: 711-9.
16. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 1993; 67: 216-21.
17. Stevens MFG, Hickman JA, Langdon SP et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M&B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47: 5846-52.
18. 6-methylguanine and temozolomide can reverse the resistance to chloroethylnitrosoureas of a mouse L1210 leukemia. Anticancer Res 1991; 11: 115-22.
19. Newlands ES, Blackledge GRP, Slack JA et al. Phase I trial of temozolomide. (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 1992; 65: 287-91.
20. O'Reilly SM. Newlands ES, Glaser MG et al. Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993; 29A: 940-2.
21. Blechen NM, Newlands ES, Lee SM et al. Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol 1995; 13: 910-3.
22. Jacquillat C, Khayat D, Banzet P et al. Final report on the french multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated melanoma, including patients with cerebral metastases. Cancer 1990; 66: 1873-8.
23. Jacquillat C, Khayat D, Banzet P et al. Chemotherapy by fotemustine in cerebral metastases of disseminated melanoma. Cancer Chemother Pharmacol 1990; 25: 263-9.
24. Wolrd Health Organization. Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. Geneva: WHO 1979.
25. 6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res 1991; 51: 619-23.
26. Shen F, Decosterd LA, Gander M et al. Determination of temozolomide in human plasma and urine by high-performance liquid chromatography after solid-phase extraction. J Chromatogr Biomed Appl 1995; 667: 291-300.
27. Marzolini C, Decosterd LA, Shen F et al. Pharmacokinetics of temozolomide in association with fotemustine in malignant melanoma and malignant glioma patients: Comparison of oral, intravenous and hepatic intraarterial administration. Cancer Chemother Pharmacol 1998; 42: 433-40.
28. Shah VP, Midha KK, Dighe S et al. Analytical methods validation: Bioavailability, bioequivalence, and pharmacokinetic studies. Conference report. Eur J Drug Metab Pharmacokinet 1991; 16: 249-55.
29. 6-methylguanine-DNA methyltransferase in individual human cells by quantitative immunofluorescence microscopy. Oncol Res 1994; 6: 129-37.
30. 6-methylguanine-DNA methyltransferase. Cancer Chemother Pharmacol 1996; 37: 547-55.
31. Fisher RA, Yates F. Statistical Tables for Biological, Agricultural and Medical Research. Edinburgh: Oliver and Boyd 1974.
32. 6-alkylguanine alkyltransferase-directed DNA repair in metastatic colon cancers. J Clin Oncol 1995; 13: 2301-8.
33. 6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Chemother Pharmacol 1993; 32: 59-63.
34. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer 1994; 69: 452-6.
35. 6-Methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours. Br J Cancer 1995; 71: 37-9.
36. Kobayashi K, Jodrell DI, Ratain MJ. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv 1993; 17: 51-78.
37. Kobayashi K, Ratain MJ. Individualizing dosing of cancer chemotherapy. Semin Oncol 1993; 20: 30-42.
38. Dolan ME, Roy SK, Fasanmade AA et al. 06-benzylguanine in humans: Metabolic, phamacokinetic and pharmacodynamic findings. J Clin Oncol 1998; 16: 1803-7.
39. 6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 1998; 16: 3570-5.
40. 6-benzylguanine (BG) plus carmustine (BCNU) in patients with advanced cancer. Proc Am Soc Clin Oncol 1998; 17: 198a (Abstr).